Nihon Pharmaceutical
As of the edition of 20 October 2026, Nihon Pharmaceutical runs 10 drugs, 7 of them marketed; it is on route A at 0 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Went quiet | 3 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tacrolimus anhydrous | Ends 2028 (exclusivity) | 3 |
| Magnesium sulfate anhydrous | none listed | 0 |
| Magnesium | none listed | 0 |
| Sodium sulfate anhydrous | none listed | 0 |
| Levomenthol | none listed | 2 |
| Potassium | none listed | 0 |
| Potassium sulfate | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 2 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Nihon Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Digestive system: 1 trials led